Tuberculosis Nanobody
Tuberculosis
Pre-clinicalActive
Key Facts
About VicuTec Biologicals
VicuTec Biologicals is a private, preclinical-stage biotech based in Munich and Dortmund, Germany, developing a robust nanobody platform. The company's technology, originating from the Max Planck Institute and University Medical Center Göttingen, enables rapid, cost-effective production of highly potent nanobodies in microbial systems. Its initial pipeline targets major infectious diseases including COVID-19, MRSA, Tuberculosis, and Malaria, with backing from the EU Malaria Fund and strategic academic partnerships.
View full company profileTherapeutic Areas
Other Tuberculosis Drugs
| Drug | Company | Phase |
|---|---|---|
| Vaxine TB Vaccine | Vaxine | Preclinical |
| Isoniazid Oral Solution, USP | CMP Pharma | Approved |
| Tuberculosis Program | Fimbrion Therapeutics | Preclinical |
| Undisclosed Program | Crestone | Preclinical |
| Tuberculosis Diagnostic | GenEndeavor | Research/Exploratory |
| TB Screening LFA | DiagMetrics | Development |
| RGFields for Tuberculosis | Anapole Technologies | Pre-clinical |
| Not specified on provided pages | Cadila Pharmaceuticals | Commercial (World's First Claim) |
| TB Diagnostic & Drug Discovery | Avesthagen | Research/Discovery |
| ALF Platform | Senzo | Pre-clinical |
| Satiro Tablets | KYORIN Pharmaceutical | Registration |